Diagnostic Assays for theJAK2V617F Mutation in Chronic Myeloproliferative Disorders

[1]  A. Tefferi,et al.  Mutation screening for JAK2V617F: when to order the test and how to interpret the results. , 2006, Leukemia research.

[2]  J. Maciejewski,et al.  Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. , 2006, American journal of clinical pathology.

[3]  W. Vainchenker,et al.  Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis , 2006, Leukemia.

[4]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.

[5]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[6]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[7]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[8]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[9]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[10]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[11]  R. McClure,et al.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.

[12]  A. Green,et al.  Essential thrombocythemia. , 2003, Hematology/oncology clinics of North America.